Abstract
In recent years, an increase in invasive VRE infections has been reported worldwide, including Germany. The most common gene encoding resistance to glycopeptides is VanA, but predominant VanB clones are emerging. Although neither the incidence rates nor the exact routes of nosocomial transmission of VRE are well established, screening and strict infection control measures, e.g. single room contact isolation, use of personal protective clothing by hospital staff and intensified surface disinfection for colonized individuals, are implemented in many hospitals. At the same time, the impact of VRE infection on mortality remains unclear, with current evidence being weak and contradictory. In this short review, we aim to give an overview on the current basis of evidence on the clinical effectiveness of infection control measures intended to prevent transmission of VRE and to put these findings into a larger perspective that takes further factors, e.g. VRE-associated mortality and impact on patient care, into account.
Similar content being viewed by others
References
ECDC. Surveillance atlas of infectious diseases. 2018. Accessed 16 Aug 2018.
Remschmidt C, et al. Continuous increase of vancomycin resistance in enterococci causing nosocomial infections in Germany—10 years of surveillance. Antimicrob Resist Infect Control. 2018;7:54.
Werner G, et al. Enterococcus faecium strains from bloodstream infections of German hospital patients revealed a preferred prevalence of ST117 and an increasing number of vanB-type VRE between 2011 and 2017. In: European Congress of Microbiology and Infectious Diseases, Madrid; 2018.
McDermott H, et al. Vancomycin-resistant enterococci (VRE) in the intensive care unit in a nonoutbreak setting: identification of potential reservoirs and epidemiological associations between patient and environmental VRE. Infect Control Hosp Epidemiol. 2018;39:40–5.
Rosko AE, et al. Vancomycin-resistant enterococci infection: not just for the transplanted. Leuk Lymphoma. 2014;55:1320–5.
Chen CH, et al. Clinical and microbiological characteristics of vancomycin-resistant Enterococcus faecium bloodstream infection in Central Taiwan. Medicine (Baltimore). 2017;96:e9000.
Webb BJ, et al. Prediction of bloodstream infection due to vancomycin-resistant enterococcus in patients undergoing leukemia induction or hematopoietic stem-cell transplantation. Clin Infect Dis. 2017;64:1753–9.
Taur Y, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905–14.
DiazGranados CA, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41:327–33.
Cho SY, et al. Impact of vancomycin resistance on mortality in neutropenic patients with enterococcal bloodstream infection: a retrospective study. BMC Infect Dis. 2013;13:504.
Mahony AA, et al. Vancomycin-resistant Enterococcus faecium sequence type 796—rapid international dissemination of a new epidemic clone. Antimicrob Resist Infect Control. 2018;7:44.
Moulin E, et al. Vancomycine-resistant enterococci (VRE): a new reality in our hospitals. Rev Med Suisse. 2018;14:791–4.
Wagenvoort JH, et al. Environmental survival of vancomycin-resistant Enterococcus faecium. J Hosp Infect. 2011;77:282–3.
van Hal SJ, et al. Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation. J Antimicrob Chemother. 2018;73:1487–91.
Yeh KM, et al. Vancomycin-resistant enterococcus (VRE) carriage and infection in intensive care units. Microb Drug Resist. 2004;10:177–83.
Amberpet R, et al. Risk factors for intestinal colonization with vancomycin resistant enterococci’ a prospective study in a level III pediatric intensive care unit. J Lab Physicians. 2018;10:89–94.
Liss BJ, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40:613–9.
Gedik H, et al. Vancomycin-resistant enterococci colonization and bacteremia in patients with hematological malignancies. J Infect Dev Ctries. 2014;8:1113–8.
Biehl LM, Stemler HP, Gillis J, Peter M, Dörfel S, Vogel W, Kern WV, Gölz H, Bertz H, Rohde H, Klupp EM, Schafhausen P, Salmanton-García J, Ertel J, Zweigner J, Seifert H, Vehreschild MJGT, Impact of single room contact precautions on hospital-acquisition and transmission of vancomycin-resistant enterococci in a high-risk setting: preliminary results from the CONTROL study||Oral #O0177 in 28th ECCMID, Madrid; 2018.
Kamboj M, et al. The changing epidemiology of vancomycin-resistant enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant. 2010;16:1576–81.
Ornstein MC, et al. Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. Leuk Lymphoma. 2015;56:2536–42.
Tavadze M, et al. Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:1310–6.
Vydra J, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:764–70.
Ford CD, et al. Frequency, risk factors, and outcomes of vancomycin-resistant enterococcus colonization and infection in patients with newly diagnosed acute leukemia: different patterns in patients with acute myelogenous and acute lymphoblastic leukemia. Infect Control Hosp Epidemiol. 2015;36:47–53.
Ford CD, et al. The clinical impact of vancomycin-resistant enterococcus colonization and bloodstream infection in patients undergoing autologous transplantation. Transpl Infect Dis. 2015;17:688–94.
Satlin MJ, et al. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014;55:2858–65.
Hefazi M, et al. Vancomycin-resistant enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016;18:913–20.
Fournier S, Brun-Buisson C, Jarlier V. Twenty years of antimicrobial resistance control programme in a regional multi hospital institution, with focus on emerging bacteria (VRE and CPE). Antimicrob Resist Infect Control. 2012;1:9.
Huang SS, et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368:2255–65.
Martin EM, et al. Elimination of routine contact precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: a retrospective quasi-experimental study. Infect Control Hosp Epidemiol. 2016;37:1323–30.
Bardossy AC, et al. Evaluation of contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. Am J Infect Control. 2017;45:1369–71.
Bearman G, et al. Impact of discontinuing contact precautions for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: an interrupted time series analysis. Infect Control Hosp Epidemiol. 2018;39:676–82.
Marra AR, et al. Discontinuing contact precautions for multidrug-resistant organisms: a systematic literature review and meta-analysis. Am J Infect Control. 2018;46:333–40.
Wenzel RP, Edmond MB. Infection control: the case for horizontal rather than vertical interventional programs. Int J Infect Dis. 2010;14:S3–S5.
Pidot SJ, et al. Increasing tolerance of hospital Enterococcus faecium to handwash alcohols. Sci Transl Med, 2018;10:eaar6115. https://doi.org/10.1126/scitranslmed.aar6115.
Frakking FNJ, et al. Recommendations for the successful control of a large outbreak of vancomycin-resistant Enterococcus faecium in a non-endemic hospital setting. J Hosp Infect. 2018;21:S0195–6701(18)30109–9. https://doi.org/10.1016/j.jhin.2018.02.016.
Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA. 2003;290:1899–905.
Morgan DJ, et al. Adverse outcomes associated with contact precautions: a review of the literature. Am J Infect Control. 2009;37:85–93.
Abad C, Fearday A, Safdar N. Adverse effects of isolation in hospitalised patients: a systematic review. J Hosp Infect. 2010;76:97–102.
Martin EM, et al. Noninfectious hospital adverse events decline after elimination of contact precautions for MRSA and VRE. Infect Control Hosp Epidemiol. 2018;39:788–96.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
LMB has received lecture honoraria from Astellas and Merck/MSD, and travel grants from 3M and Gilead. MJGTV is a consultant to: Alb-Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Berlin Chemie, DaVolterra, MaaT Pharma and Merck/MSD; has served at the speakers’ bureau of: Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, Pfizer; received research funding from: 3M, Astellas Pharma, DaVolterra, Gilead Sciences, MaaT Pharma, Merck/MSD, Morphochem, Organobalance, Seres Therapeutics.
Rights and permissions
About this article
Cite this article
Vehreschild, M.J.G.T., Haverkamp, M., Biehl, L.M. et al. Vancomycin-resistant enterococci (VRE): a reason to isolate?. Infection 47, 7–11 (2019). https://doi.org/10.1007/s15010-018-1202-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-018-1202-9